Gastritis News and Research

RSS
Gastritis is not a single disease, but several different conditions that all have inflammation of the stomach lining. Gastritis can be caused by drinking too much alcohol, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen, or infection with bacteria such as Helicobacter pylori (H. pylori). Sometimes gastritis develops after major surgery, traumatic injury, burns, or severe infections. Certain diseases, such as pernicious anemia, autoimmune disorders, and chronic bile reflux, can cause gastritis as well.
As California welcomes Ukrainian refugees, counties fall short on interpreters

As California welcomes Ukrainian refugees, counties fall short on interpreters

New sensor accurately determines the human saliva pH

New sensor accurately determines the human saliva pH

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Exploring vitamin D and acute COVID-19 infection

Exploring vitamin D and acute COVID-19 infection

Study confirms accuracy of new generation GastroPanel® test

Study confirms accuracy of new generation GastroPanel® test

New study reveals oral opaganib's potent in vitro activity against Omicron

New study reveals oral opaganib's potent in vitro activity against Omicron

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

Study reveals new way viruses trigger autoimmunity

Study reveals new way viruses trigger autoimmunity

Faxes and snail mail: Will pandemic-era flaws unleash improved health technology?

Faxes and snail mail: Will pandemic-era flaws unleash improved health technology?

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Cholestenone could be a new antibacterial drug against H. pylori

Cholestenone could be a new antibacterial drug against H. pylori

Study finds a bacterial molecule that may be key to fighting gastric cancer

Study finds a bacterial molecule that may be key to fighting gastric cancer

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

A new method to determine how carcinogenic bacteria reach their targets

A new method to determine how carcinogenic bacteria reach their targets

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms